CAR T cells cross over to successfully treat autoimmune disease

Sept. 22, 2022
Reported success in treating patients with SLE.

German researchers reported success in treating patients with systemic lupus erythematosus (SLE) using chimeric antigen receptor (CAR) T-cell therapy. All five patients included in the compassionate-use study achieved disease remission after 3 months, and remission lasted a median of 8 months. The findings were published in Nature Medicine.

SLE is the most common type of lupus, a disease in which the body’s immune system attacks its own tissues, causing widespread inflammation and damage. The disease can affect joints, skin, brain, lungs, kidneys and blood vessels. SLE not only significantly impairs patient quality of life but can also be fatal, with the most patients dying from associated cardiovascular disease.

The patients (four women and one man), median age 22 years, had disease that was refractory to several immunosuppressive drug treatments.

T cells were collected from patients, genetically modified, expanded and reinfused. CAR T cells expanded in vivo led to deep depletion of B cells, improvement of clinical symptoms and normalization of laboratory parameters, including seroconversion of anti-double-stranded DNA antibodies.

Not only did the therapy deplete B cells — improving clinical symptoms and lab measurements — when new B cells were produced, they were naïve — unexposed to antigens.

The investigators are planning a basket clinical trial, which will include patients with various forms of severe autoimmune disease, such as psoriasis, rheumatoid arthritis and alopecia areata.

AABB release